AR018535A1 - CONJUGATES OF ONE OR MORE FRAGMENTS OF ANTIBODIES COVALENTLY UNITED TO ONE OR MORE MOLECULES OF NON-PROTEIC POLYMER, A COMPOSITION THAT INCLUDES THEMSELVES AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT TO TREAT AN INFLAMMATORY DISORDER. - Google Patents

CONJUGATES OF ONE OR MORE FRAGMENTS OF ANTIBODIES COVALENTLY UNITED TO ONE OR MORE MOLECULES OF NON-PROTEIC POLYMER, A COMPOSITION THAT INCLUDES THEMSELVES AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT TO TREAT AN INFLAMMATORY DISORDER.

Info

Publication number
AR018535A1
AR018535A1 ARP990100260A ARP990100260A AR018535A1 AR 018535 A1 AR018535 A1 AR 018535A1 AR P990100260 A ARP990100260 A AR P990100260A AR P990100260 A ARP990100260 A AR P990100260A AR 018535 A1 AR018535 A1 AR 018535A1
Authority
AR
Argentina
Prior art keywords
conjugate
molecules
composition
conjugates
fragments
Prior art date
Application number
ARP990100260A
Other languages
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/003337 external-priority patent/WO1998037200A2/en
Priority claimed from US09/121,952 external-priority patent/US6458355B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR018535A1 publication Critical patent/AR018535A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un conjugado que consiste esencialmente en uno o más fragmentos de anticuerpo covalentemente unido a una o más moléculas de polímero noproteico, que el tamano aparente del conjugado es de por lo menos aproximadamente 500 kD, y unacomposi cion que los comprende. El conjugado exhibe una vidamedia considerablemente mejorada, al igual que un mejor tiempo de permanencia medio y/o velocidad de clearance en circulacion en comparacion con el fragmentode anticuerpo parental sinderivar. Tambi én describe el uso del conjugado fragmento-polímero anti-IL-8 donde el tamano aparente del conjugado es mayor que 500KD para el tratamiento de desordenes inflamatorios.A conjugate is described which consists essentially of one or more antibody fragments covalently bound to one or more molecules of noprotein polymer, which the apparent size of the conjugate is at least about 500 kD, and a composition comprising them. The conjugate exhibits a considerably improved half-life, as well as a better average residence time and / or circulation clearance rate compared to the sinderivant parental antibody fragment. It also describes the use of the anti-IL-8 fragment-polymer conjugate where the apparent size of the conjugate is greater than 500KD for the treatment of inflammatory disorders.

ARP990100260A 1998-01-22 1999-01-22 CONJUGATES OF ONE OR MORE FRAGMENTS OF ANTIBODIES COVALENTLY UNITED TO ONE OR MORE MOLECULES OF NON-PROTEIC POLYMER, A COMPOSITION THAT INCLUDES THEMSELVES AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT TO TREAT AN INFLAMMATORY DISORDER. AR018535A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1211698A 1998-01-22 1998-01-22
PCT/US1998/003337 WO1998037200A2 (en) 1997-02-21 1998-02-20 Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
US12251398A 1998-07-24 1998-07-24
US09/121,952 US6458355B1 (en) 1998-01-22 1998-07-24 Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates

Publications (1)

Publication Number Publication Date
AR018535A1 true AR018535A1 (en) 2001-11-28

Family

ID=45606491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100260A AR018535A1 (en) 1998-01-22 1999-01-22 CONJUGATES OF ONE OR MORE FRAGMENTS OF ANTIBODIES COVALENTLY UNITED TO ONE OR MORE MOLECULES OF NON-PROTEIC POLYMER, A COMPOSITION THAT INCLUDES THEMSELVES AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT TO TREAT AN INFLAMMATORY DISORDER.

Country Status (3)

Country Link
AR (1) AR018535A1 (en)
AU (1) AU2559799A (en)
WO (1) WO1999037779A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
CA2615918C (en) 1997-02-21 2013-11-26 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
WO2001094420A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
EP2292273A3 (en) * 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
DK2144923T3 (en) 2007-04-03 2013-05-13 Biogenerix Ag METHODS OF TREATMENT WITH USING GLYCOPEGYLATED G-CSF
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
CA2823812C (en) 2011-01-14 2017-02-14 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
RU2016122041A (en) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи NEW ANTI-CLAUDIN ANTIBODIES AND WAYS OF THEIR APPLICATION
JP2017500028A (en) 2013-12-12 2017-01-05 アッヴィ・ステムセントルクス・エル・エル・シー Novel anti-DPEP3 antibody and method of use
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
US9321812B2 (en) * 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
TW201617368A (en) 2014-09-05 2016-05-16 史坦森特瑞斯公司 Novel anti-MFI2 antibodies and methods of use
MX2020006171A (en) 2018-01-12 2020-09-03 Bristol Myers Squibb Co Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer.
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0749488A1 (en) * 1994-03-03 1996-12-27 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
AU701342B2 (en) * 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8

Also Published As

Publication number Publication date
AU2559799A (en) 1999-08-09
WO1999037779A1 (en) 1999-07-29

Similar Documents

Publication Publication Date Title
AR018535A1 (en) CONJUGATES OF ONE OR MORE FRAGMENTS OF ANTIBODIES COVALENTLY UNITED TO ONE OR MORE MOLECULES OF NON-PROTEIC POLYMER, A COMPOSITION THAT INCLUDES THEMSELVES AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT TO TREAT AN INFLAMMATORY DISORDER.
CY1118363T1 (en) ANTIBODIES CONNECTED TO BLYS
CY1119353T1 (en) ANTI-CS1 ANTIBODY TREATMENT USE
ATE474854T1 (en) RSV NEUTRALIZING ANTIBODIES WITH VERY HIGH AFFINITY
CY1109454T1 (en) Treatment for Alzheimer's disease and vascular cerebral amyloidopathy
DE69932084D1 (en) Antibody fragments for the local treatment of eye diseases
DK0841949T3 (en) Use of saccharide conjugates
DE122012000001I1 (en) Human antibodies against CTLA-4 and their uses.
BR9815580A (en) Vaccine composition, processes to generate an anti-idiotype response in a subject, to treat or prevent cancer, to treat or prevent an infectious disease, to prepare a first immunoglobulin molecule, and, first immunoglobulin molecule
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
BR0315157A (en) Methods of treating alzheimer's disease by employing antibodies directed against amyloid beta peptide and compositions thereof
EP1415998A3 (en) Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
CY1109525T1 (en) HUMANIZED ANTI-ErbB2 ANTIBODIES AND THERAPEUTIC TREATMENT WITH ANTI-ErbB2 ANTIBODIES
BRPI0414435A (en) methods and reagents for the treatment of immunoinflammatory disorders
WO2002043570A3 (en) METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
PT696326E (en) UTILIZATION OF NDV IN THE MANUFACTURE OF A CANCER TREATMENT MEDICINE
ES2121791T3 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF A MALIGNANT TUMOR.
EE200100645A (en) Prevention and treatment of amyloidogenic disease
NO177526C (en) Process for the preparation of pharmaceutically active conjugates
ES2115618T3 (en) USE OF ANTI-ICAM ANTIBODIES IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF ENDOTOXIN SHOCK.
BR0111869A (en) Cyclic compounds fused as modulators of receptor function for nuclear homonium
DE69915977D1 (en) Novel heparin binding peptides
FR2768622B1 (en) Rosacea extract as antagonist of bradykinin
EA200100976A1 (en) MACROMOLECULAR COMPOUNDS
DE69230798D1 (en) RECOMBINANT IMMUNTOXINE

Legal Events

Date Code Title Description
FG Grant, registration